The Hypomethylation Agent Bisdemethoxycurcumin Acts on the WIF-1 Promoter, Inhibits the Canonical Wnt Pathway and Induces Apoptosis in Human Non-Small-Cell Lung Cancer

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|11|9|1098-1110

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.11, Iss.9, 2011-11, pp. : 1098-1110

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting the eicosanoid pathway in non-small-cell lung cancer

By Horn Leora   Backlund Michael   Johnson David H  

Expert Opinion on Therapeutic Targets, Vol. 13, Iss. 6, 2009-06 ,pp. : 675-688

Informa Healthcare

Access to resources Recommend Favorite

Spotlight on Gefitinib in Non-Small-Cell Lung Cancer

By Frampton James E.   Easthope Stephanie E.  

American Journal of PharmacoGenomics, Vol. 5, Iss. 2, 2005-01 ,pp. : 133-136

Adis International

Access to resources Recommend Favorite

Vandetanib for the treatment of non-small-cell lung cancer

By Wong Hui-li   de Boer Richard H  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 14, 2011-10 ,pp. : 2271-2278

Informa Healthcare

Access to resources Recommend Favorite

Emerging drugs for non-small-cell lung cancer

By Felip Enriqueta   Santarpia Mariacarmela   Rosell Rafael  

Expert Opinion on Emerging Drugs, Vol. 12, Iss. 3, 2007-09 ,pp. : 449-460

Informa Healthcare

Access to resources Recommend Favorite

Non-canonical IKKs, IKKε and TBK1, as novel therapeutic targets in the treatment of non-small cell lung cancer

By Kim Jae-Young   Beg Amer A   Haura Eric B  

Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 10, 2013-10 ,pp. : 1109-1112

Informa Healthcare

Access to resources Recommend Favorite